Page 1

EX - 99.1 2 nbix - 20210331exhibit991.htm EX - 99.1 Neurocrine Biosciences Reports First Quarter 2021 Financial Results INGREZZA® ( valbenazine ) First Quarter 2021 Net Product Sales of $ 230 Million with Approximately 43,300 TRx Initiated Pediatric Phase III Registrational Program of Crinecerfont for the Treatment of Classic Congenital Adrenal Hyperplasia Initiated Phase II Study of NBI - 827104 in Essential Tremor SAN DIEGO , May 5 , 2021 - Neurocrine Biosciences , Inc. ( Nasdaq : NBIX ) today announced its financial results for the first quarter ended March 31 , 2021 and provided revised full - year 2021 financial expense guidance . " Our first quarter results reflect a lower than normal refill rate per patient due to the typical seasonal payor dynamics for INGREZZA that were exacerbated by COVID . Importantly , we did not see an increase in discontinuations and exited the quarter with more patients on INGREZZA versus the prior quarter . New patient starts did pick up late in the quarter and we are focused on restoring INGREZZA growth as the impact of the pandemic wanes , " said Kevin Gorman , Ph.D. , Chief Executive Officer of Neurocrine Biosciences . “ We made meaningful progress advancing our large , growing and diverse pipeline , including initiating a registrational study for the treatment of pediatric patients with congenital adrenal hyperplasia and a Phase II study in essential tremor . With important commercial products addressing patient needs and on track to initiate nine mid - to - late stage clinical studies this year , we are executing our plan to build a leading neuroscience - based company . " Financial Highlights ( unaudited , in millions , except per share data ) Revenues : Product sales , net Collaboration revenue Total revenues GAAP Research and Development ( R & D ) Non - GAAP R & D GAAP Selling , General and Administrative ( SG & A ) Non - GAAP SG & A GAAP net income GAAP net income per share – diluted Non - GAAP net income Non - GAAP net income per share – diluted ( unaudited , in millions ) Total cash , cash equivalents and debt securities available - for - sale $ | $ $ LA LA $ $ LA LA $ LA LA $ LA LA $ $ $ Three Months Ended March 31 , 2021 231.0 $ 5.6 236.6 $ 73.2 58.2 129.0 $ 32.1 0.33 $ $ 111.1 $ LA LA March 31 , 2021 Exhibit 99.1 1,123.3 47.9 $ 0.49 $ $ $ $ 2020 231.1 6.0 237.1 58.3 50.6 117.8 102.7 37.4 0.39 79.1 0.82 December 31 , 2020 1,028.1